Local sustained release of prostaglandin E1 induces neovascularization in murine hindlimb ischemia

Circulation Journal

Volumn 73, Issue 7, 2009, Pages 1330-1336

  Esaki, Jiro ^a   Sakaguchi, Hisashi ^a   Marui, Akira ^a   Bir, Shyamal Chandra ^a   Arai, Yoshio ^a   Huang, Yuhong ^a   Tsubota, Hideki ^a   Kanaji, Toshiya ^b   Ikeda, Tadashi ^a   Sakata, Ryuzo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Angiogenesis; Peripheral vascular disease; Poly lactide co glycolide; Prostaglandin E1; Sustained release

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MICROSPHERE; POLYGLACTIN; PROSTAGLANDIN E1; PROSTAVASIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; HINDLIMB; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; LIMB PERFUSION; MALE; MOUSE; MUSCLE ISCHEMIA; NONHUMAN; PARTICLE SIZE; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TREATMENT DURATION;

ALPROSTADIL; ANIMALS; BLOOD VESSELS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HINDLIMB; ISCHEMIA; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; MICROSPHERES; NEOVASCULARIZATION, PHYSIOLOGIC; POLYGLYCOLIC ACID;

EID: 68149179328     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0999     Document Type: Article

References (32)

1. Makino H, Aoki M, Hashiya N, Yamasaki K, Hiraoka K, Shimizu H, et al. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. Hypertens Res 2004; 27: 85-91. (Pubitemid 38325179)
2. Marchesi S, Pasqualini L, Lombardini R, Vaudo G, Lupattelli G, Pirro M, et al. Prostaglandin E1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol 2003; 41: 249-253. (Pubitemid 36135250)
3. Mehrabi MR, Ekmekcioglu C, Stanek B, Thalhammer T, Tamaddon F, Pacher R, et al. Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E1. J Heart Lung Transplant 2001; 20: 465-473. (Pubitemid 32297757)
4. Mehrabi MR, Serbecic N, Tamaddon F, Kaun C, Huber K, Pacher R, et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res 2002; 56: 214-224. (Pubitemid 35223492)
5. Mehrabi MR, Serbecic N, Tamaddon F, Pacher R, Horvath R, Mall G, et al. Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: Stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed Pharmacother 2003; 57: 173-178. (Pubitemid 36734806)
6. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
7. Marui A, Kanematsu A, Yamahara K, Doi K, Kushibiki T, Yamamoto M, et al. Simultaneous application of basic fibroblast growth factor and hepatocyte growth factor to enhance the blood vessels formation. J Vasc Surg 2005; 41: 82-90. (Pubitemid 40193345)
8. Arai Y, Fujita M, Marui A, Hirose K, Sakaguchi H, Ikeda T, et al. Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia. Circ J 2007; 71: 412-417. (Pubitemid 46409547)
9. Golub M, Zia P, Matsuno M, Horton R. Metabolism of prostaglandins A1 and E1 in man. J Clin Invest 1975; 56: 1404-1410.
10. Cawello W, Schweer H, Muller R, Bonn R, Seyberth HW. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. Eur J Clin Pharmacol 1994; 46: 275-277. (Pubitemid 24137440)
11. Doi K, Ikeda T, Marui A, Kushibiki T, Arai Y, Hirose K, et al. Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels 2007; 22: 104-108. (Pubitemid 46510550)
12. Huang Y, Marui A, Sakaguchi H, Esaki J, Arai Y, Hirose K, et al. Sustained release of prostaglandin E(1) potentiates the impaired therapeutic angiogenesis by basic fibroblast growth factor in diabetic murine hindlimb ischemia. Circ J 2008; 72: 1693-1699.
13. Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003; 18: 93-99. (Pubitemid 36701553)
14. Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, et al. Toward surgical angiogenesis using slow-released basic fibroblast growth factor. Eur J Cardiothorac Surg 2003; 24: 105-112. (Pubitemid 36802349)
15. Bir SC, Fujita M, Marui A, Hirose K, Arai Y, Sakaguchi H, et al. New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia. Circ J 2007; 72: 633-640. (Pubitemid 351695392)
16. Haider DG, Bucek RA, Giurgea AG, Maurer G, Glogar H, Minar E, et al. PGE1 analog alprostadil induces VEGF and eNOS expression in endothelial cells. Am J Physiol Heart Circ Physiol 2005; 289: H2066-H2072. (Pubitemid 41507358)
17. Cattaneo MG, Pola S, Deho V, Sanguini AM, Vicentini LM. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine matrigel plug assay. Br J Pharmacol 2003; 138: 377-385. (Pubitemid 36188599)
18. Weiss TW, Mehrabi MR, Kaun C, Zorn G, Kastl SP, Speidl WS, et al. Prostaglandin E1 induces vascular endothelial growth factor-1 in human adult cardiac myocytes but not in human adult cardiac fibroblasts via a cAMP-dependent mechanism. J Mol Cell Cardiol 2004; 36: 539-546. (Pubitemid 38469944)
19. Gensch C, Clever Y, Werner C, Hanhoun M, Bohm M, Laufs U. Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis. J Mol Cell Cardiol 2007; 42: 670-677. (Pubitemid 46357555)
20. Baum O, Da Silva-Azevedo L, Willerding G, Wockel A, Planitzer G, Gossrau R, et al. Endothelial NOS is main mediator for shear stress-dependent angiogenesis in skeletal muscle after prazosin administration. Am J Physiol Heart Circ Physiol 2004; 287: H2300-H2308. (Pubitemid 39430770)
21. Sumi M, Sata M, Hashimoto A, Imaizumi T, Yanaga K, Ohki T, et al. OPC-28326, a selective femoral arterial vasodilator, augments ischemia induced angiogenesis. Biomed Pharmacother 2007; 61: 209-215. (Pubitemid 46686978)
22. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 1143-1151.
23. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 2003; 38: 198-203.
24. Eguchi S, Kawano T, Yinhua, Tanaka K, Yasui S, Mawatari K, et al. Effects of prostaglandin E1 on vascular ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2007; 50: 686-691. (Pubitemid 350307039)
25. + channels inhibits proliferation of human endothelial cells induced by basic fibroblast growth factor. J Vasc Res 1998; 35: 363-371. (Pubitemid 28503465)
26. + channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2005; 25: 704-709. (Pubitemid 40463857)
27. Gianetti J, De Caterina M, de Cristofaro T, Ungaro B, Guercio RD, De Caterina R. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease. Am Heart J 2001; 142: 733-739. (Pubitemid 32900503)
28. Weiss C, Regele S, Velich T, Bartsch P, Weiss T. Hemostasis and fibrinolysis in patients with intermittent claudication: Effects of prostaglandin E1. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 271-277.
29. Schellong S, Altmann E, von Bilderling P, Rudofsky G, Waldhausen P, Rogatti W. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: A randomized cross-over study in patients with critical limb ischemia. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 503-509. (Pubitemid 38621893)
30. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1: The ICAI Study Group [Ischemia Cronica degli Arti Inferiori]. Ann Intern Med 1999; 130: 412-421.
31. Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006; 43: 752-759.
32. Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, et al. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg 2007; 45: 953-961. (Pubitemid 46634915)